Celgene joined investors including Alexandria Venture Investments to expand the cell therapy developer's series B round by an extra $11m.
US-based cell therapy developer Nohla Therapeutics has reached the $56m second close of a series B round featuring pharmaceutical firm Celgene and life sciences real estate developer Alexandria Real Estate Equities.
Financial services and investment group Fidelity Management and Research (FMR) also took part in the round, as did University of Tokyo Edge Capital, Schroder Adveq, Premier Partners, Arch Venture Partners, 5AM Ventures and AML Biotech Partners.
Alexandria Real Estate Equities participated through its venture capital arm, Alexandria Venture Investments,…
